AIMS: To evaluate the incidence and outcome of acute myeloid leukaemia (AML), FAB M6 (erythroleukaemia). METHODS: A demographic study in the Northern Health Region of England between 1983 and 1999. RESULTS: Thirty three cases were diagnosed and registered prospectively. The overall incidence was 0.077 cases/100,000/year. There was a pronounced rise in incidence in patients aged 56 years or more: 6.6 times higher than that in younger patients. Overall survival was poor; median survival was 11 months for those aged less than 56 years, and three months for patients aged 56 years and above (p = 0.045). Acquired karyotypic abnormalities were found in 17 of 27 patients where analysis was attempted. When classified according to the criteria of the Medical Research Council AML trials, karyotype predicted survival, with a median overall survival of 14 months for those with "standard risk" cytogenetic results and two months for "poor risk" results (p = 0.005). CONCLUSION: This study demonstrates a worse survival for patients with erythroleukaemia than that reported in some published trials of selected patients.
AIMS: To evaluate the incidence and outcome of acute myeloid leukaemia (AML), FAB M6 (erythroleukaemia). METHODS: A demographic study in the Northern Health Region of England between 1983 and 1999. RESULTS: Thirty three cases were diagnosed and registered prospectively. The overall incidence was 0.077 cases/100,000/year. There was a pronounced rise in incidence in patients aged 56 years or more: 6.6 times higher than that in younger patients. Overall survival was poor; median survival was 11 months for those aged less than 56 years, and three months for patients aged 56 years and above (p = 0.045). Acquired karyotypic abnormalities were found in 17 of 27 patients where analysis was attempted. When classified according to the criteria of the Medical Research Council AML trials, karyotype predicted survival, with a median overall survival of 14 months for those with "standard risk" cytogenetic results and two months for "poor risk" results (p = 0.005). CONCLUSION: This study demonstrates a worse survival for patients with erythroleukaemia than that reported in some published trials of selected patients.
Authors: J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan Journal: Ann Intern Med Date: 1985-10 Impact factor: 25.391
Authors: A Cuneo; A Van Orshoven; J L Michaux; M Boogaerts; A Louwagie; C Doyen; P Dal Cin; F Fagioli; G Castoldi; H Van den Berghe Journal: Br J Haematol Date: 1990-07 Impact factor: 6.998
Authors: O I Olopade; M Thangavelu; R A Larson; R Mick; A Kowal-Vern; H R Schumacher; M M Le Beau; J W Vardiman; J D Rowley Journal: Blood Date: 1992-12-01 Impact factor: 22.113
Authors: F R Davey; N Abraham; V L Brunetto; J M MacCallum; D A Nelson; E D Ball; J D Griffin; M R Baer; D Wurster-Hill; R J Mayer Journal: Am J Hematol Date: 1995-05 Impact factor: 10.047
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: R Su; L Dong; D Zou; H Zhao; Y Ren; F Li; P Yi; L Li; Y Zhu; Y Ma; J Wang; F Wang; J Yu Journal: Oncogene Date: 2016-04-18 Impact factor: 9.867
Authors: Sa A Wang; Keyur P Patel; Olga Pozdnyakova; Jie Peng; Zhuang Zuo; Paola Dal Cin; David P Steensma; Robert P Hasserjian Journal: Mod Pathol Date: 2016-07-15 Impact factor: 7.842
Authors: N Ping; A Sun; Y Song; Q Wang; J Yin; W Cheng; Y Xu; L Wen; H Yao; L Ma; H Qiu; C Ruan; D Wu; S Chen Journal: Leukemia Date: 2016-06-15 Impact factor: 11.528
Authors: Jacob Abraham Linu; Ms Namratha Udupa; D S Madhumathi; K C Lakshmaiah; K Govind Babu; D Lokanatha; Mc Suresh Babu; K N Lokesh; L K Rajeev; A H Rudresha Journal: Ecancermedicalscience Date: 2017-01-10